Overview

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the MEK Inhibitor Binimetinib (MEK162) for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer

Status:
Recruiting

Trial end date:
2024-03-31

Target enrollment:

Participant gender:

Summary

This trial is being conducted as a possible treatment for lung cancer with a specific change in the KRAS gene. The drugs involved in this study are: - Palbociclib - Binimetinib

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborators:

Array BioPharma
Pfizer

Treatments:

Palbociclib